Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/459| Title: | The financial burden of using Oncotype Dx for patients with lymph node-negative and estrogen receptor-positive breast cancer in Australia | Authors: | Sakata, S. Cronk, M. |
Issue Date: | 2014 | Source: | March 10, (1), 2014, p. 94-95 | Pages: | 94-95 | Journal: | Asia-Pacific Journal of Clinical Oncology | DOI: | http://dx.doi.org/10.1111/ajco.12077 | Resources: | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed11&AN=2014127653 | Keywords: | Australiacancer chemotherapy;cancer diagnosis;cancer patient;cancer recurrence;cancer risk;cancer size;cancer survival;clinical feature;clinical practice;cost effectiveness analysis;cost of illness;disease free survival;early cancer;estrogen receptor positive breast cancer/di [Diagnosis];estrogen receptor positive breast cancer/dm [Disease Management];human;letter;life expectancy;lymph node;medical decision making;practice guideline;priority journal;quality adjusted life year;quality of life;cyclophosphamide;docetaxel;epidermal growth factor receptor 2/ec [Endogenous Compound];estrogen receptor/ec [Endogenous Compound];Ki 67 antigen/ec [Endogenous Compound];progesterone receptor/ec [Endogenous Compound] | Type: | Article |
| Appears in Sites: | Sunshine Coast HHS Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.